Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2024-04-15 DOI:10.1080/14728214.2024.2339906

Francis Proulx-Rocray, Denis Soulières

引用次数: 0

Abstract

The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing, particularly among younger populations. It is projected that the number of new cases will increase by almost 50% by 204...

查看原文本刊更多论文

治疗头颈部鳞状细胞癌的新兴单克隆抗体疗法

头颈部鳞状细胞癌 (HNSCC) 的发病率正在上升，尤其是在年轻人群中。预计到 204 年，新发病例的数量将增加近 50%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.